Research · Sep 3, 2026
[RGEN] Repligen Corporation Thesis 2026: Bioprocessing Consumables Drive Filtration Chromatography Cyclical Recovery
Repligen Corporation (NASDAQ: RGEN) is a US bioprocessing technology company, founded 1981 in Waltham Massachusetts, that supplies chromatography, filtration, process analytics, proteins and fluid management products to biopharma monoclonal antibody (mAb), cell & gene therapy, vaccine, bispecific and ADC manufacturers plus CDMOs. RGEN enters FY2026 with FY2025 revenue ~$0.65-0.75B (+5-15% YoY off the $0.64B FY2024 trough) and adj. EPS ~$1.50-1.95, reflecting a ~$0.28-0.34B Filtration franchise + ~$0.18-0.22B Chromatography franchise + ~$0.10-0.14B Process Analytics franchise + ~$0.08-0.12B Proteins franchise + Fluid Management revenue mix, all under President + CEO Olivier Loeillot (CEO since 2024, ~1-2 year tenure; ex-Sartorius bioprocess executive with GE Healthcare Life Sciences background; succeeded Tony Hunt after his ~9-year 2015-2024 tenure). The first thesis pillar is the Filtration + Chromatography Bioprocessing Consumables pipeline (~$0.46-0.56B revenue, ~70-74% revenue mix): tangential flow filtration (TFF) single-use flat-sheet cassettes, hollow fiber, XCell ATF cell retention, OPUS pre-packed chromatography columns and ready-to-use single-use chromatography, with ~80%+ aggregate consumables/recurring revenue mix, riding the post-2024-2025 bioprocessing cyclical recovery as biopharma and CDMO customer inventory destocking and capex normalization that depressed 2022-2024 reverse into FY2025-FY2026 restocking plus mAb commercial and clinical pipeline demand and cell & gene therapy and vaccine demand; FY2026 catalyst is ~$0.48-0.62B combined Filtration + Chromatography revenue (~+8-18% growth) at ~30-37% adj. operating margin on cyclical recovery operating leverage. The second pillar is the Process Analytics + Proteins + Fluid Management pipeline (~$0.18-0.24B revenue, ~26-30% revenue mix): at-line and in-line process analytical technology (PAT) including FlowVPX and SoloVPE variable pathlength spectroscopy for real-time bioprocess monitoring; Protein A ligands as OEM supply to chromatography resin manufacturers (Cytiva, Purolite); single-use assemblies, tubing and connectors; FY2026 catalyst is ~$0.19-0.26B combined revenue (~+8-18% growth) plus PAT adoption and cross-sell. The capital story: no regular dividend and no FY2025 buybacks (capital reinvestment, organic growth and tuck-in M&A priority), ~$0.7-1.0B aggregate cash and investments, net cash position (net debt negative; ~$0.5-0.8B convertible notes), ~$0+ net leverage, non-rated to investment-grade credit profile, ~57-60M diluted shares; the balance sheet funds organic growth, R&D and bioprocessing technology bolt-ons. At ~$100-180 per share on ~57-60M shares (~$6-11B market cap) RGEN trades at ~30-50x P/E versus bioprocessing and life-science-tools peers Sartorius, Danaher/Cytiva, Thermo Fisher Scientific, Merck KGaA/MilliporeSigma, Donaldson, Entegris, Bio-Techne, Bruker, Mettler-Toledo, Avantor and West Pharmaceutical Services. FY2026 base case is ~$0.70-0.85B revenue + ~$1.90-2.50 adj. EPS on a net cash balance sheet; bull case ~$0.78-0.95B revenue + ~$2.40-3.10 EPS on consumables recovery acceleration plus PAT and Proteins growth plus tuck-in M&A; bear case ~$0.62-0.72B revenue + ~$1.40-1.90 EPS on competitive intensification from Sartorius and Cytiva, prolonged biopharma and CDMO destocking, biopharma R&D funding cycle weakness, single-use versus stainless steel mix shifts, biosimilar and China biopharma headwinds, slow PAT adoption and CEO succession-planning considerations. The thesis depends on the Filtration + Chromatography consumables franchise plus Process Analytics + Proteins + Fluid Management growth plus ~80%+ consumables/recurring revenue mix plus the post-2024-2025 bioprocessing cyclical recovery plus the net cash balance sheet plus tuck-in M&A and Olivier Loeillot's organic-growth execution.